Skip to main content
. 2018 Aug 14;32(8):512–522. doi: 10.1007/s12149-018-1291-7

Fig. 1.

Fig. 1

Whole-body maximum intensity projection images with normal biodistribution of a prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) (using [18F]-DCFPyL) and b somatostatin receptor (SSTR)-targeted PET (using [68Ga]-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ([68Ga]DOTATOC)). No abnormal radiotracer uptake can be appreciated. In both RADS systems (PSMA- and SSTR-RADS), these would be classified as RADS-1A [1820]. For a PSMA-targeted PET, the normal biodistribution includes radiotracer uptake in the lacrimal glands, salivary glands, liver, spleen, kidneys, and small bowel. In addition, radiotracer is seen being excreted within the urinary tract.

Modified from Rowe et al. [19], © by the Society of Nuclear Medicine and Molecular Imaging, Inc. For b SSTR-targeted PET, the normal biodistribution includes radiotracer uptake in the pituitary gland, major salivary glands, thyroid, adrenal glands, liver, and spleen. Similar to PSMA-targeted PET, radiotracer excretion via the urinary tract can be appreciated. The arrow indicates physiological normal variant uptake in the uncinate. Modified from Werner et al. [20], © by the Society of Nuclear Medicine and Molecular Imaging, Inc.